US Stock MarketDetailed Quotes
ABUS Arbutus Biopharma
- 3.460
- -0.010-0.29%
Close Nov 29 13:00 ET
- 3.540
- +0.080+2.30%
Post 17:01 ET
655.64MMarket Cap-8046P/E (TTM)
3.505High3.455Low315.40KVolume3.470Open3.470Pre Close1.09MTurnover0.23%Turnover RatioLossP/E (Static)189.49MShares4.72552wk High6.13P/B471.32MFloat Cap1.98052wk Low--Dividend TTM136.22MShs Float31.480Historical High--Div YieldTTM1.44%Amplitude0.821Historical Low3.468Avg Price1Lot Size
Arbutus Biopharma Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 4.81%-20.74M | 25.84%-14.5M | 29.32%-19.3M | -143.06%-85.94M | -1.78%-17.29M | -16.54%-21.78M | 3.62%-19.56M | -232.41%-27.3M | 47.65%-35.36M | 13.34%-16.99M |
| Net income from continuing operations | 1.92%-19.72M | -15.81%-19.8M | -9.40%-17.88M | -4.89%-72.85M | 11.95%-19.31M | -14.44%-20.1M | -20.45%-17.09M | -3.64%-16.34M | 8.91%-69.46M | -2.87%-21.93M |
| Operating gains losses | ---- | ---- | ---- | ---20K | --0 | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization | -8.94%336K | 4.09%356K | 6.29%355K | -1.61%1.4M | 16.94%359K | 7.58%369K | -10.70%342K | -15.23%334K | -18.60%1.43M | -28.10%307K |
| Other non cash items | 57.63%-200K | 73.56%-326K | 46.75%-377K | 9.60%-3.34M | -171.93%-930K | 72.27%-472K | -23.55%-1.23M | -7.93%-708K | -166.81%-3.7M | 75.47%-342K |
| Change In working capital | 26.11%-2.5M | 168.88%2.76M | 76.82%-2.86M | -162.35%-18.23M | -57.68%1.49M | -141.57%-3.38M | 47.41%-4M | -135.50%-12.33M | 3,061.41%29.24M | 249.65%3.51M |
| -Change in receivables | -64.11%159K | 644.00%372K | 72.33%-363K | 6.40%-424K | -18.22%395K | 228.15%443K | 107.61%50K | -216.91%-1.31M | -209.69%-453K | -37.11%483K |
| -Change in prepaid assets | 181.00%1.19M | 206.42%116K | 66.67%-156K | -138.81%-943K | -54.35%1.1M | -226.89%-1.46M | -128.61%-109K | 68.94%-468K | 337.07%2.43M | 350.84%2.4M |
| -Change in payables and accrued expense | -456.04%-3.56M | 437.38%2.86M | 68.26%-2.02M | -210.39%-5.76M | -87.63%465K | 590.69%1M | -122.54%-848K | -203.33%-6.38M | 172.95%5.22M | 183.56%3.76M |
| -Change in other current liabilities | -9.86%-156K | -6.85%-78K | 2.70%-72K | -9.63%-444K | -25.00%-155K | -7.58%-142K | 1.35%-73K | 1.33%-74K | -8.29%-405K | 5.34%-124K |
| -Change in other working capital | 96.18%-123K | 83.04%-513K | 94.05%-244K | -147.49%-10.66M | 89.53%-315K | -36.95%-3.22M | 72.57%-3.02M | -110.57%-4.1M | --22.46M | ---3.01M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 4.81%-20.74M | 25.84%-14.5M | 29.32%-19.3M | -143.06%-85.94M | -1.78%-17.29M | -16.54%-21.78M | 3.62%-19.56M | -232.41%-27.3M | 47.65%-35.36M | 13.34%-16.99M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -214.93%-11.99M | 582.10%9.83M | -29.88%11.69M | 167.75%50.77M | 75.25%22.23M | 175.91%10.43M | 110.42%1.44M | 127.77%16.68M | -491.12%-74.94M | 256.16%12.68M |
| Net PPE purchase and sale | --0 | 99.88%-1K | 18.80%-95K | -92.97%-988K | --0 | 86.81%-12K | -347.40%-859K | -56.00%-117K | 36.71%-512K | -165.52%-154K |
| Net business purchase and sale | ---- | ---- | 0.50%37.19M | ---- | ---- | ---- | ---- | --37M | ---- | ---- |
| Net investment purchase and sale | -214.80%-11.99M | 19.63%47.02M | -25.70%-25.4M | 169.54%51.76M | 73.15%22.23M | 176.51%10.44M | 388.17%39.3M | 66.31%-20.21M | -527.10%-74.43M | 259.20%12.84M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -214.93%-11.99M | 582.10%9.83M | -29.88%11.69M | 167.75%50.77M | 75.25%22.23M | 175.91%10.43M | 110.42%1.44M | 127.77%16.68M | -491.12%-74.94M | 256.16%12.68M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 5.59%1.78M | 413.92%24.37M | 19.66%24.43M | -3.67%30.65M | -65.65%3.81M | -81.59%1.68M | 4,096.46%4.74M | 77.77%20.42M | -76.82%31.81M | -81.25%11.08M |
| Net common stock issuance | --0 | 371.51%22.36M | 9.58%21.77M | 46.88%29.85M | -65.24%3.85M | -84.44%1.4M | --4.74M | 7,311.19%19.86M | -84.91%20.32M | -81.29%11.08M |
| Proceeds from stock option exercised by employees | 522.81%1.78M | --2.01M | 380.18%2.67M | -93.08%795K | -4,600.00%-45K | 79.25%285K | --0 | -95.05%555K | 346.91%11.49M | 100.87%1K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 5.59%1.78M | 413.92%24.37M | 19.66%24.43M | -3.67%30.65M | -65.65%3.81M | -81.59%1.68M | 4,096.46%4.74M | 77.77%20.42M | -76.82%31.81M | -81.25%11.08M |
| Net cash flow | ||||||||||
| Beginning cash position | 130.86%62.79M | 6.23%43.1M | -14.59%26.29M | -71.84%30.78M | -26.97%17.53M | -42.53%27.2M | -50.11%40.57M | -71.84%30.78M | 109.15%109.28M | -69.18%24M |
| Current changes in cash | -219.90%-30.95M | 247.24%19.7M | 71.83%16.83M | 94.25%-4.52M | 28.98%8.74M | 58.48%-9.67M | 60.67%-13.38M | 135.04%9.79M | -237.63%-78.48M | -78.42%6.78M |
| Effect of exchange rate changes | -37.50%5K | -700.00%-8K | -425.00%-13K | 213.64%25K | 450.00%14K | 144.44%8K | ---1K | --4K | -540.00%-22K | -180.00%-4K |
| End cash Position | 81.66%31.85M | 130.86%62.79M | 6.23%43.1M | -14.59%26.29M | -14.59%26.29M | -26.97%17.53M | -42.53%27.2M | -50.11%40.57M | -71.84%30.78M | -71.84%30.78M |
| Free cash flow | 4.95%-20.74M | 28.96%-14.51M | 29.28%-19.39M | -142.40%-86.94M | -0.98%-17.29M | -16.15%-21.82M | 0.42%-20.42M | -233.46%-27.42M | 47.52%-35.87M | 12.92%-17.12M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data